Assessing the effectiveness of Upadacitinib in treating ulcerative colitis

Early therapeUtic RespOnse and Predictivity of Long-term Effectiveness of Upadacitinib in Ulcerative Colitis (EUROPE)

Observational AbbVie · NCT05496348

This study is testing how well Upadacitinib works for adults with moderate to severe ulcerative colitis by following their treatment over two years.

Quick facts

Study typeObservational
Enrollment400 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsUpadacitinib
Locations94 sites (Vienna, State of Vienna and 93 other locations)
Trial IDNCT05496348 on ClinicalTrials.gov

What this trial studies

This observational study evaluates the effectiveness of Upadacitinib, an approved medication for ulcerative colitis, in adult patients diagnosed with active moderate to severe ulcerative colitis. Approximately 400 participants will be enrolled across Germany, Austria, and Switzerland, and will receive Upadacitinib as part of their routine clinical care. The study will follow participants for up to two years, collecting data during regular hospital or clinic visits without imposing additional burdens. The treatment decision will be made independently by the investigator based on local guidelines.

Who should consider this trial

Good fit: Ideal candidates include adults with an endoscopically confirmed diagnosis of active moderate to severe ulcerative colitis who are initiating treatment with Upadacitinib.

Not a fit: Patients who have contraindications to Upadacitinib or those previously exposed to a Janus kinase (JAK) inhibitor may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness of Upadacitinib for managing ulcerative colitis, potentially improving patient outcomes.

How similar studies have performed: Other studies have shown positive outcomes with Upadacitinib in treating ulcerative colitis, indicating that this approach is supported by prior evidence.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants with an endoscopically confirmed diagnosis of active moderate to severe Ulcerative colitis (UC).
* Participants initiating Upadacitinib (UPA) at the investigator's discretion as part of their routine clinical care; the decision to administer UPA must be made prior to and independent of documentation for the study and according to the approved local label.
* Participants able to understand and communicate with the investigator and comply with the requirements of the study.
* Participants willing to continue with study documentation after cessation of UPA.

Exclusion Criteria:

* Participants with any contraindication to Upadacitinib (UPA).
* Participants previously exposed to a Janus kinase (JAK) inhibitor.

Where this trial is running

Vienna, State of Vienna and 93 other locations

+44 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Ulcerative ColitisUlcerative colitisUCUpadacitinibUPARINVOQ
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.